Apollo to acquire a minority stake in Sofinnova for €1bn.

Apollo, an alternative asset manager, agreed to acquire a minority stake in Sofinnova, a life sciences venture capital firm, for €1bn. “The life sciences industry continues to grow and innovate, creating significant opportunities to fund and advance new therapeutics and technologies in pursuit of better health outcomes. Today, Apollo and its affiliates manage more than $5 billion across the healthcare and life sciences industries, and we view this space as a significant growth area for the firm. Sofinnova is a clear partner of choice, with specialized knowledge and a vast industry network that is accretive to our broader investing platform. Together we can leverage our complementary strengths and cultures to form a long-term, mutually beneficial relationship,” Scott Kleinman, Apollo Co-President.